We just finished reading a terrific academic piece by Jack Scannell and colleagues at the University of Oxford. Entitled Financial Returns on R&D: Looking Back at History, Looking Forward…
Last week Reuters published an article summarizing the "virtual" biotech business model. It was a strange article, considering that this is not a new approach. Indeed, we wrote about this…
These past few weeks I have noticed how negative and bimodal we have become when clinical results are announced. More and more, Phase II and III results are labeled #FAIL…
Lisa Jarvis has prepared a handy overview of the new drug approvals in 2014: For the pharmaceutical industry, 2014 was one for the record books: sky-high merger and acquisition activity, unprecedented…
Today, Bruce Booth published yet another terrific post, where he discusses the current biotech investment bubble from the private world of venture backed biotechs (and, he puts many mainstream journalists…
Mind The Gap... We're late to this party, but a really good interview of David Grainger from Index Ventures was published in July of this year. We encourage you to read…
The new DiMasi estimates for R&D costs were published this week. You can get a PDF of their slides here, while Ed Silverman has a nice summary in the WSJ. According…
Earlier this week, The Economist travels over well-trod ground in an article on pharmaceutical industry M&A: It used to be all about achieving sheer scale, and building a broad portfolio…
There's more to Wyoming than this. In Part One of his series, Dr. Garrett Lindemann discussed some of the challenges facing Wyoming as it grows its life science industry. In Part…
This morning, California-based Avanir Pharmaceuticals announced that their combination of dextromethorphan HBr and quinidine sulfate (AVP-923) hit their Phase II endpoints in Alzheimer's Disease: Treatment with AVP-923 was associated…